Summary of medicine characteristics - ReproCyc ParvoFLEX
-
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
ReproCyc ParvoFLEX suspension for injection for pigs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
Active substance:
Porcine Parvovirus strain 27a VP2 subunit antigen > 1.0 RP*
-
* Relative Potency (ELISA)
Adjuvant:
Carbomer 2 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection.
Colourless to slightly brown, opalescent suspension.
4. CLINICAL PARTICULARS4.1 Target species
Pigs
-
4.2 Indications for use, specifying the target species
For active immunisation of gilts and sows from the age of 5 months to protect progeny against transplacental infection caused by porcine parvovirus.
Onset of immunity: from the beginning of the gestational period.
Duration of immunity: 6 months
4.3 Contraindications
None.
-
4.4 Special warnings for each target species
Vaccinate healthy animals only.
-
4.5 Special precautions for use
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Not applicable.
-
4.6 Adverse reactions (frequency and seriousness)
Transient redness or swelling (up to 4 cm) caused by the injection procedure is very common. Local reactions resolve within two to five days without treatment. An elevation in the body temperature after vaccination is common which resolves spontaneously within 24 to 48 hours.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated , including isolated reports).
-
4.7 Use during pregnancy, lactation and lay
Can be used during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with ReproCyc PRRS EU and administered at one injection site.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
-
4.9 Amounts to be administered and administration route
Shake well before use.
Avoid introduction of contamination during use.
Primary vaccination scheme:
For pigs previously non-vaccinated against porcine parvovirus:
Two intramuscular injections of one dose, 3 weeks apart.
The second dose being given at least 3 weeks before mating.
Re-vaccination scheme:
One intramuscular injection of one dose at least every 6 months is recommended in a whole herd programme (see section 4.2).
Mixing with ReproCyc PRRS EU:
The full content of one vial of ReproCyc ParvoFLEX should be used to reconstitute the lyophilisate of one vial of ReproCyc PRRS EU. ReproCyc ParvoFLEX hereby replaces the solvent of ReproCyc PRRS EU.
Ensure that the lyophilisate is completely reconstituted before use.
Administer a single dose (2 ml) of the mixture intramuscularly.
The following corresponding presentations (doses) can be mixed:
| ReproCyc ParvoFLEX | ReproCyc PRRS EU (lyophilisate) |
| 10 doses (20 ml) | 10 doses |
| 50 doses (100 ml) | 50 doses |
| 100 doses (200 ml) | 100 doses |
The package leaflet of ReproCyc PRRS EU should also be consulted before the administration of the mixed product.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No data available.
-
4.11 Withdrawal period(s)
Zero days.
-
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for Suidae, inactivated viral vaccines, porcine parvovirus
ATCvet code: QI09AA02
This vaccine is designed to stimulate the development of an active immune response in pigs to porcine parvovirus.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Carbomer
Sodium chloride
Water for injections
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate anhydrous
6.2 Major incompatibilities
Do not mix with any other veterinary medicinal product, except with ReproCyc PRRS EU.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Shelf life after first opening the immediate packaging: 8 hours
Shelf life after mixing with ReproCyc PRRS EU: 8 hours
6.4 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Keep the bottle in the outer carton in order to protect from light.
-
6.5 Nature and composition of immediate packaging
High density polyethylene bottles containing 20 ml (10 doses), 100 ml (50 doses) and 200 ml (100 doses). Each bottle is closed with a rubber stopper and an aluminium cap.
1 bottle of 20 ml (10 doses), 100 ml (50 doses) or 200 ml (100 doses) packed in a cardboard box.
12 bottles of 20 ml (10 doses), 100 ml (50 doses) or 200 ml (100 doses) packed in a cardboard box.
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANY
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/19/237/001–006
-
9. DATE OF AUTHORISATION/RENEWAL OF THE AUTHORISATION